GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Myos Rens Technology Inc (NAS:MYOS) » Definitions » Intrinsic Value: DCF (Dividends Based)

Myos Rens Technology (Myos Rens Technology) Intrinsic Value: DCF (Dividends Based) : $ (As of May. 05, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Myos Rens Technology Intrinsic Value: DCF (Dividends Based)?

As of today (2024-05-05), Myos Rens Technology's intrinsic value calculated from the Discounted Dividend model is $.

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star) with dividend payments. If the company's Predictability Rank is 1-Star or Not Rated, or if the company does not pay dividend, the data will not be stored into our database.

Myos Rens Technology's Predictability Rank is Not Rated. Thus, this page is only used for demonstration purposes and the DCF related results in the screener and portfolio will appear as zero.

Margin of Safety % (DCF Dividends Based) using Discounted Dividend Model for Myos Rens Technology is

The historical rank and industry rank for Myos Rens Technology's Intrinsic Value: DCF (Dividends Based) or its related term are showing as below:

MYOS's Price-to-DCF (Dividends Based) is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.2
* Ranked among companies with meaningful Price-to-DCF (Dividends Based) only.

Myos Rens Technology Intrinsic Value: DCF (Dividends Based) Historical Data

The historical data trend for Myos Rens Technology's Intrinsic Value: DCF (Dividends Based) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myos Rens Technology Intrinsic Value: DCF (Dividends Based) Chart

Myos Rens Technology Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Intrinsic Value: DCF (Dividends Based)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Myos Rens Technology Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Intrinsic Value: DCF (Dividends Based) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Myos Rens Technology's Intrinsic Value: DCF (Dividends Based)

For the Drug Manufacturers - Specialty & Generic subindustry, Myos Rens Technology's Price-to-DCF (Dividends Based), along with its competitors' market caps and Price-to-DCF (Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myos Rens Technology's Price-to-DCF (Dividends Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Myos Rens Technology's Price-to-DCF (Dividends Based) distribution charts can be found below:

* The bar in red indicates where Myos Rens Technology's Price-to-DCF (Dividends Based) falls into.



Myos Rens Technology Intrinsic Value: DCF (Dividends Based) Calculation

This is the intrinsic value calculated from the Discounted Dividend Model with default parameters. The calculation method is the same as Discounted Cash Flow model except adjusted dividend are used in the calculation instead of free cash flow. This is the default method of calculation with GuruFocus DCF calculator.

Usually a two-stage model is used in calculating the intrinsic value with discounted cash flow model. The first stage is called growth stage; the second is called the terminal stage. In the growth stage the company grows at a faster rate. Because it cannot grow at that rate forever, a lower rate is used for the terminal stage.

GuruFocus DDM calculator is a two-stage model. The default values are defined as:

1. Discount Rate: d = 11%
A reasonable discount rate assumption should be at least the long term average return of the stock market, which can be estimated from risk free rate plus risk premium of stock market. GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate and rounded up to the nearest integer. It is updated daily. The current risk-free rate is 4.50%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default. Then we added a risk premium of 6% to get the estimated discount rate. Some investors use their expected rate of return, which is also reasonable. A typical discount rate can be anywhere between 6% - 20%.

2. Dividend Growth Rate in the growth stage: g1 = %
The Growth Rate in the growth stage is initially set as the default 10-Year Dividend Growth Rate. In cases where the 10-year growth rate is unavailable, it defaults to using the 5-Year Dividend Growth Rate. If both the 10-year and 5-year growth rates are unavailable, the system defaults to the 3-Year Dividend Growth Rate.
However, it's important to note that there is a growth rate range. If the calculated growth rate exceeds 20%, it will be capped at 20%. Conversely, if the calculated growth rate falls below 5%, it will be adjusted to 5% to maintain a reasonable range.
=>

3. Years of Growth Stage: y1 = 10

4. Terminal Growth Rate: g2 = 4%

5. Dividends per Share: adjusted dividends per share = $.
GuruFocus uses adjusted dividends per share by default to ensure that the valuation reflects the total value of the company, as the actual dividend is only a portion of the total value.

All of the default settings can be changed in the DCF calculator and the results are calculated automatically.

Myos Rens Technology's Intrinsic Value: DCF (Dividends Based) for today is calculated as:

Intrinsic Value: DCF (Dividends Based)=Dividends per Share*{[(1+g1)/(1+d)+(1+g1)^2/(1+d)^2+...+(1+g1)^10/(1+d)^10]
+(1+g1)^10/(1+d)^10*[(1+g2)/(1+d)+(1+g2)^2/(1+d)^2+...+(1+g2)^10/(1+d)^10]}

set x = (1+g1)/(1+d) = (1+)/(1+0.11) =
and y = (1+g2)/(1+d) = (1+)/(1+0.11) =

Intrinsic Value: DCF (Dividends Based)=Dividends per Share*{[x+x^2+...+x^10]+x^10*[y+y^2+...+y^10]}
=Dividends per Share*[x*(1-x^10)/(1-x)+x^10*y*(1-y^10)/(1-y)]
=*
=

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based)-Current Price) /Intrinsic Value: DCF (Dividends Based)
= ( - 12.12) /

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myos Rens Technology  (NAS:MYOS) Intrinsic Value: DCF (Dividends Based) Explanation

Unlike valuation methods such as Net Current Asset Value, Tangible Book per Share, Graham Number, Median PS Value etc, discounted Dividends model evaluates the companies based on their power of future dividend distribution instead of their assets.


Be Aware

What you need to know about Discounted Dividends model:

1. The Discounted Dividends model evaluates a company based on its future dividends distribution power
2. Dividend growth is taken into account; therefore a company with a higher dividend growth rate is worth more if everything else is the same.
3. Since we are projecting future growth, it is assumed that the company will grow at the same rate as it did during the past 10 years. Therefore this model works better for the companies with consistently steady dividends distributed.
4. The Discounted Dividends model works poorly for inconsistent dividends distributor like high growth companies.
5. Your expected return from the investment is a reasonable discount rate assumption.
6. A larger margin of safety should be required for companies with less dividends distributed.

You can screen for stocks that trade below their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) and Intrinsic Value: DCF (Dividends Based) with the GuruFocus All-in-One Screener. Companies with a high Predictability Rank that trade at a discount to their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) can be found in the screen of Undervalued Predictable Companies.


Myos Rens Technology Intrinsic Value: DCF (Dividends Based) Related Terms

Thank you for viewing the detailed overview of Myos Rens Technology's Intrinsic Value: DCF (Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Myos Rens Technology (Myos Rens Technology) Business Description

Industry
Traded in Other Exchanges
N/A
Address
45 Horsehill Road, Suite 106, Cedar Knolls, NJ, USA, 07927
Myos Rens Technology Inc is a US-based bio-nutrition and biotherapeutics company. It focuses on the discovery, development, and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. The company develops nutritional and therapeutic products for maintaining and improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases such as Sarcopenia, Cachexia, and others.
Executives
Joseph Mannello director, officer: Chief Executive Officer C/O BREAN CAPITAL, LLC, 1345 AVENUE OF THE AMERICAS, 29TH FLOOR, NEW YORK NY 10105
Victor E Mandel director PO BOX 5962, WASHINGTON DC 20016
Robert J Hariri director 341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Christopher Pechock director C/O MATLINPATTERSON GLOBAL ADVISORS INC, 520 MADISON AVE, NEW YORK NY 10022-4213
Christopher C Dewey director 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271
Louis J. Aronne director 4640 ADMIRALTY, SUITE 500, MARINA DEL RAY CA 90292
Eric Zaltas director 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ 07927
Andrew Joel Ponte director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
David J Matlin 10 percent owner
John Nosta director 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS NJ 07927
Zhengguang Lyu director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Ren Ren director, 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Rens Technology Inc 10 percent owner 150 DRAKE STREET ROOM 7F, POMONA CA 91767
Rens Agriculture Science & Technology Co, Ltd 10 percent owner 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019
Guiying Zhao director 16TH FLOOR, BUILDING A, FENGHUO PLAZA, NO.88 YUN LONG SHAN ROAD, NANJING F4 210019

Myos Rens Technology (Myos Rens Technology) Headlines

From GuruFocus

MYOS CEO Joseph Mannello Issues Letter to Shareholders

By PRNewswire PRNewswire 01-09-2020